Evidence map›Paper›PMID 41760314›Full record

ArticleIn vivo (Athens, Greece)

Drug-induced Aseptic Meningitis: Pharmacovigilance Analysis of Japanese Adverse Event Reporting Database.

Sho Masago, Kazumasa Kotake, Kenta Yamaoka, Kennosuke Yorifuji, Tadashi Shimizu

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sho MasagoDepartment of Pharmacy, Shinko Hospital, Kobe, Japan; masago.sho@shinkohp.or.jp.
Kazumasa KotakeDepartment of Pharmacy, Zikei Hospital/Zikei Institute of Psychiatry, Okayama, Japan.
Kenta YamaokaGraduate School of Pharmacy, Hyogo Medical University, Kobe, Japan.
Kennosuke YorifujiDepartment of Pharmacy, Shinko Hospital, Kobe, Japan.
Tadashi ShimizuGraduate School of Pharmacy, Hyogo Medical University, Kobe, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimDrug-induced aseptic meningitis (DIAM) is a rare but clinically important adverse event. We identified drugs potentially associated with aseptic meningitis using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND

methodsWe conducted a disproportionality analysis of aseptic meningitis adverse events using JADER data from April 2004 to October 2024. Disproportionality signals for aseptic meningitis were detected using reporting odds ratios (RORs) with 95% confidence intervals. The Weibull distribution was analyzed to evaluate the time to onset of adverse events for drugs producing symptoms of aseptic meningitis.

resultsNineteen drugs were identified as associated with aseptic meningitis: nine vaccines, three immunoglobulin products, two nonsteroidal anti-inflammatory drugs, and two immune checkpoint inhibitors (nivolumab and ipilimumab), among others. The onset of DIAM temporally associated with the SARS-CoV-2 RNA vaccine was typically observed within a few days following vaccination, resembling the temporal pattern reported for conventional DIAM. In contrast, the DIAM onset after nivolumab and ipilimumab treatment was delayed, leading to the classification of these drugs as random failure types, which is consistent with the timing of the immune-related adverse events.

conclusionDIAM onset patterns differ among therapeutic classes, including immune checkpoint inhibitors and SARS-CoV-2 RNA vaccines. These differences in onset timing suggest that DIAM onset occurs through distinct pathophysiological mechanisms. This information may support differential diagnosis and guide management of aseptic meningitis in clinical settings.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsMeningitis, AsepticPharmacovigilanceAdultAgedCOVID-19 VaccinesDatabases, FactualFemaleHumansImmune Checkpoint InhibitorsJapanMaleMiddle AgedmRNA VaccinesCOVID-19 VaccinesImmune Checkpoint InhibitorsmRNA Vaccinesadverse eventAseptic meningitisimmune checkpoint inhibitorpharmacovigilanceSARS-CoV-2 vaccine

Identifiers

PMID41760314
PMCPMC12949876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.